These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 18089780)

  • 61. Study of events leading cellular senescence to human mammary epithelial cancer cells in vitro.
    Saxena S; Jain AK; Bhatnagar D
    Indian J Cancer; 2001; 38(2-4):103-16. PubMed ID: 12593448
    [TBL] [Abstract][Full Text] [Related]  

  • 62. IGFBP-3 expression in hepatocellular carcinoma involves abnormalities in TGF-beta and/or Rb signaling pathways.
    Yumoto E; Nakatsukasa H; Hanafusa T; Yumoto Y; Nouso K; Matsumoto E; Onishi T; Takuma Y; Tanaka H; Fujikawa T; Suzuki M; Uemura M; Shiratori Y
    Int J Oncol; 2005 Nov; 27(5):1223-30. PubMed ID: 16211216
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Chromatin epigenetic modifications in cancer generation].
    Arenas-Huertero F; Recillas-Targa F
    Gac Med Mex; 2002; 138(6):547-55. PubMed ID: 12532619
    [TBL] [Abstract][Full Text] [Related]  

  • 64. 17-beta-estradiol affects nuclear image properties in MCF-10F human breast epithelial cells with tumorigenesis.
    Mello ML; Russo P; Russo J; Vidal BC
    Oncol Rep; 2007 Dec; 18(6):1475-81. PubMed ID: 17982633
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Growth regulatory factors and carcinogenesis: the roles played by transforming growth factor beta, its receptors and signaling pathways.
    Kelly DL; Rizzino A
    Anticancer Res; 1999; 19(6A):4791-807. PubMed ID: 10697593
    [TBL] [Abstract][Full Text] [Related]  

  • 66. TGF-beta signaling in breast cancer.
    Buck MB; Knabbe C
    Ann N Y Acad Sci; 2006 Nov; 1089():119-26. PubMed ID: 17261761
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Induced epigenetic modifications of the promoter chromatin silence survivin and inhibit tumor growth.
    Ma AN; Huang WL; Wu ZN; Hu JF; Li T; Zhou XJ; Wang YX
    Biochem Biophys Res Commun; 2010 Mar; 393(4):592-7. PubMed ID: 20152814
    [TBL] [Abstract][Full Text] [Related]  

  • 68. AP2 transcription factors regulate expression of CRABPII in hormone responsive breast carcinoma.
    McPherson LA; Woodfield GW; Weigel RJ
    J Surg Res; 2007 Mar; 138(1):71-8. PubMed ID: 17187826
    [TBL] [Abstract][Full Text] [Related]  

  • 69. DNA methylation disturbances as novel therapeutic target in lung cancer: preclinical and clinical results.
    Digel W; Lübbert M
    Crit Rev Oncol Hematol; 2005 Jul; 55(1):1-11. PubMed ID: 15886007
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A genetic screen for candidate tumor suppressors identifies REST.
    Westbrook TF; Martin ES; Schlabach MR; Leng Y; Liang AC; Feng B; Zhao JJ; Roberts TM; Mandel G; Hannon GJ; Depinho RA; Chin L; Elledge SJ
    Cell; 2005 Jun; 121(6):837-48. PubMed ID: 15960972
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Suppression of viral gene expression in bovine leukemia virus-associated B-cell malignancy: interplay of epigenetic modifications leading to chromatin with a repressive histone code.
    Merimi M; Klener P; Szynal M; Cleuter Y; Kerkhofs P; Burny A; Martiat P; Van den Broeke A
    J Virol; 2007 Jun; 81(11):5929-39. PubMed ID: 17392371
    [TBL] [Abstract][Full Text] [Related]  

  • 72. TGF-β: friend or foe? The role of TGF-β/SMAD signaling in epigenetic silencing of ovarian cancer and its implication in epigenetic therapy.
    Chou JL; Chen LY; Lai HC; Chan MW
    Expert Opin Ther Targets; 2010 Nov; 14(11):1213-23. PubMed ID: 20925461
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Loss of betaglycan expression in ovarian cancer: role in motility and invasion.
    Hempel N; How T; Dong M; Murphy SK; Fields TA; Blobe GC
    Cancer Res; 2007 Jun; 67(11):5231-8. PubMed ID: 17522389
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Alterations in components of the TGF-beta superfamily signaling pathways in human cancer.
    Levy L; Hill CS
    Cytokine Growth Factor Rev; 2006; 17(1-2):41-58. PubMed ID: 16310402
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Mouse models of transforming growth factor beta impact in breast development and cancer.
    Serra R; Crowley MR
    Endocr Relat Cancer; 2005 Dec; 12(4):749-60. PubMed ID: 16322320
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Chromosome 3p and breast cancer.
    Yang Q; Yoshimura G; Mori I; Sakurai T; Kakudo K
    J Hum Genet; 2002; 47(9):453-9. PubMed ID: 12202982
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Tenascin-W is found in malignant mammary tumors, promotes alpha8 integrin-dependent motility and requires p38MAPK activity for BMP-2 and TNF-alpha induced expression in vitro.
    Scherberich A; Tucker RP; Degen M; Brown-Luedi M; Andres AC; Chiquet-Ehrismann R
    Oncogene; 2005 Feb; 24(9):1525-32. PubMed ID: 15592496
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Differential tumor suppressor properties and transforming growth factor-beta responsiveness of p57KIP2 in leukemia cells with aberrant p57KIP2 promoter DNA methylation.
    Kuang SQ; Ling X; Sanchez-Gonzalez B; Yang H; Andreeff M; Garcia-Manero G
    Oncogene; 2007 Mar; 26(10):1439-48. PubMed ID: 16936778
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Isogenic normal basal and luminal mammary epithelial isolated by a novel method show a differential response to ionizing radiation.
    Huper G; Marks JR
    Cancer Res; 2007 Apr; 67(7):2990-3001. PubMed ID: 17409405
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Neuregulin-regulated gene expression in mammary carcinoma cells.
    Amin DN; Tuck D; Stern DF
    Exp Cell Res; 2005 Sep; 309(1):12-23. PubMed ID: 15963498
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.